10x Genomics Acquires Proteintech Genomics to Expand Proteomics Capabilities

Aditxt Acquires Ignite Proteomics for $36 Million

March 19, 2026

Healthcare Services

Aditxt announced the $36 million acquisition of Ignite Proteomics, a commercial-stage precision oncology company. The deal was structured through the issuance of 36,000 shares of Aditxt’s newly designated Series A-2 convertible preferred stock, and Ignite will operate as a subsidiary within Aditxt’s oncology initiatives.

10x Genomics to Acquire Scale Biosciences

August 7, 2025

Healthcare Services

10x Genomics, Inc. has signed a definitive agreement to acquire Scale Biosciences, Inc., a single-cell analysis company. The deal is intended to expand 10x’s Chromium platform with Scale’s key inventions and technologies and broaden access to scalable single-cell analysis for researchers worldwide.

Standard BioTools Acquires Sengenics from Summa Equity

November 21, 2024

Biotechnology

Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Affymetrix Acquires Panomics for Approximately $73M

November 11, 2008

Biotechnology

Affymetrix Inc. agreed to acquire Panomics Inc., a Fremont, California–based provider of low- to mid-plex genetic and protein assay products, for approximately $73 million in cash. The purchase is intended to expand Affymetrix's product portfolio and enable a more complete genetic-analysis workflow—linking whole-genome microarray studies with targeted Panomics assays—and is expected to close by the end of 2008 subject to customary conditions.